Bausch Health (BHC) Q2 2026 earnings review
Operating Leverage Accelerates, But the Xifaxan Clock is Ticking
Bausch Health delivered its 13th consecutive quarter of revenue growth (excluding Bausch + Lomb), with top-line results accelerating to 16% YoY. The volume recovery dropped violently to the bottom line—Adjusted EBITDA for the ex-B+L business surged 28%, demonstrating phenomenal operating leverage. The Salix segment remains the undisputed engine, fueled by a 26% spike in Xifaxan revenue. Management raised full-year guidance across the board on the back of $671M in operating cash flow. However, this is a race against the clock: the company is aggressively deleveraging to repair its balance sheet before 2027 IRA price cuts and a 2028 Xifaxan patent loss inevitably crush this highly profitable revenue stream.
🐂 Bull Case
Operating cash flow surged 132% YoY to $671M in Q2. Bausch is effectively using the current high-margin environment to pay down its massive debt load and extend maturities before generic competition arrives.
Xifaxan revenue accelerated to 26% YoY growth. Sustained volume expansion and AI-driven commercial efficiencies are maximizing the asset's terminal value.
🐻 Bear Case
Management has acknowledged a significant EBITDA step-down is coming in 2027 due to IRA price negotiations, followed by a generic loss of exclusivity for Xifaxan on Jan 1, 2028.
Solta reported massive 38% top-line growth, but backing out the Shibo acquisition reveals organic growth has decelerated sharply to just 12%.
⚖️ Verdict: ⚪
Neutral. Management is executing a flawless deleveraging playbook with accelerating operating metrics. However, with Xifaxan representing the lion's share of profitability, the 2028 generic cliff caps the long-term equity upside.
Key Themes
Salix Franchise Acceleration
The Salix segment is accelerating, growing 21% YoY to $758M. This was almost entirely driven by Xifaxan, which posted an incredible 26% revenue gain. The company's deployment of its AI-Enabled Customer Insights Engine continues to dramatically increase sales force productivity and drive new patient starts, proving that tech-driven commercial execution can extract new growth even from mature assets.
Solta's Organic Deceleration Hidden by M&A
On paper, the Solta aesthetics segment looks like a secondary growth engine, reporting 38% revenue growth to $176M. However, stripping out the $32M inorganic boost from the Shibo distribution acquisition in China reveals a concerning trend: organic growth decelerated to just 12%. This contradicts the narrative of an unstoppable global aesthetics expansion and suggests underlying consumer fatigue or competitive pressure in core APAC markets.
The Looming Xifaxan Cliff
The entire Bausch Health investment thesis hinges on what happens to Xifaxan. The asset faces two catastrophic hurdles: Medicare IRA price cuts taking effect in 2027, and generic entry scheduled for January 1, 2028. While management is maximizing cash flow today, the lack of a clear, scalable pipeline replacement (especially after the RED-C trial failures in 2025) means a massive structural earnings crater is essentially guaranteed within 36 months.
Macro: Tariff Impacts Fully Materializing
Management explicitly cited rapid developments in trade protectionist measures, noting that the new financial guidance now bakes in the estimated impact of applicable tariffs. While the exact gross margin degradation was not broken out, this introduces a new external headwind to profitability just as the company needs every dollar to deleverage.
Aggressive Deleveraging Execution
The company's balance sheet remains highly levered, but execution here is pristine. Bausch generated $671M in operating cash flow in Q2 (up 132% YoY). The company has systematically pushed out maturities—executing $9.6B in refinancing during 2025—leaving minimal obligations due before the end of 2027. This provides the exact runway needed to operate until the Xifaxan LOE.
International and Diversified Stabilization
The International segment provided a solid, stable foundation with 10% reported growth (5% organic) led by EMEA and LATAM. Crucially, the Diversified segment—a frequent laggard—finally stabilized. After shrinking 13% YoY in 25Q2 and 10% in 26Q1, organic growth flattened to 0%, stopping the bleeding in the neuroscience and dermatology portfolios.
Other KPIs
Accelerating dramatically. Cash generation was up 132% from $289 million in the prior year period. Total cash and cash equivalents swelled to $1.82B from $1.31B at year-end, providing significant dry powder for targeted BD or continued debt paydown.
Derived by dividing $865M Adj. EBITDA by $1,458M Revenue. This represents a substantial margin expansion versus the 54.0% margin recorded in Q2 2025, driven entirely by the high-margin flow-through of Xifaxan volume.
Reversing the massive -$1.42B GAAP loss from Q1 2026 (which was weighed down by a $1.4B goodwill impairment). EPS landed at $0.68, marking a clean, highly profitable quarter unencumbered by massive one-time accounting write-downs.
Guidance
Accelerating. Raised from prior expectations. The midpoint ($10.915B) implies roughly 6.3% YoY growth over FY25's $10.266B, indicating sustained momentum in the back half of the year despite tariff headwinds.
Accelerating. This implies roughly 8% to 11% YoY growth vs FY25. The upward revision signals high confidence that operating leverage will continue to outpace revenue growth.
Accelerating. This implies upper-single-digit growth. Management continues to extract maximum value from the legacy pharmaceutical assets.
Accelerating. Raised significantly, reflecting the massive Q2 cash generation. This metric gives Bausch exactly what it needs: liquidity to manage the $20B+ debt stack.
Key Questions
Solta Market Dynamics
Solta's reported growth was 38%, but organic growth decelerated sharply to 12%. Is this organic slowdown driven by broad APAC consumer softness, or are you seeing new competitive entrants taking share in the aesthetics device space?
Tariff Margin Degradation
You noted that guidance includes the estimated impact of applicable tariffs. Can you quantify the specific gross margin headwind these tariffs pose for the remainder of 2026 and into 2027?
Post-2028 Pipeline Gap
Given the 2028 Xifaxan LOE and the previous RED-C trial failures, you face a multi-billion dollar revenue crater. Beyond Larsucosterol, what specific late-stage BD targets are you aggressively pursuing to replace this lost EBITDA?
B+L Monetization Timing
With the debt maturity window largely cleared until late 2027, what specific milestones or valuation metrics are you waiting for before executing the sale of your 88% stake in Bausch + Lomb?